CXCR4 and glioblastoma: Active compounds extracted from CX, such as tetramethylpyrazine, n-butylidenephthalide, ferulic acid, and ligustilide, have demonstrated the ability to suppress GBM growth by inhibiting proliferation, tumor migration, invasion, and sensitizing GBM to temozolomide treatment targeting CXCR4, Rho GTPases, PI3K/Akt, ERK1/2, and Nur77 (NR4A1), thereby highlighting its potential as a therapeutic agent [10,11,12,13,14,15,16,17,18,19].